Eisai U.S. Neurology
Eisai U.S. Neurology is the U.S. subsidiary of Japan's Eisai Co., Ltd., developing and commercializing neurology therapeutics primarily for early Alzheimer's Disease through its FDA-approved LEQEMBI franchise, serving patients via healthcare providers, pharmacies, and Magnolia patient support programs.
- Company typePrivate
- Founded-
- HeadquartersNutley, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eisai U.S. Neurology does
Eisai U.S. Neurology operates the American neurology franchise of Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo and listed on the Tokyo Stock Exchange (4523). The U.S. entity (legal name Eisai Inc.) is headquartered in Nutley, New Jersey, and employs 84 staff focused on neurodegenerative disease treatments, primarily Alzheimer's Disease and sleep-wake disorders. Its flagship product is LEQEMBI (lecanemab-irmb), an FDA-approved humanized IgG1 monoclonal antibody that selectively binds to amyloid-beta (Aβ) protofibrils for the treatment of early Alzheimer's Disease; the company received FDA approval on July 13, 2026 for LEQEMBI IQLIK, a subcutaneous autoinjector formulation designed as an initiation dose to replace IV administration.
The underlying technology platform centers on four decades of accumulated Alzheimer's Disease research spanning amyloid, tau, neurodegeneration, and emerging pathway targets. The company operates the G2D2 (Groundbreaking Dementia Discovery) R&D laboratory in Cambridge, MA, which pursues next-generation immunodementia drugs using a stated "deep human biology learning" approach. The portfolio is anchored by LEQEMBI's IV formulation and the newly approved subcutaneous autoinjector, supported by clinical evidence including a real-world LEADER study showing over 75% of early Alzheimer's patients remained stable over an average 17 months of treatment.
The business operates a B2B2C pharmaceutical model: Eisai distributes LEQEMBI through HCP-directed physician networks (neurology specialists and healthcare systems), pharmacy trade relations, and the Magnolia Patient Support Programs for insurance navigation and co-pay assistance. Pricing for prescription medications is not publicly disclosed and is determined through insurance coverage and patient assistance programs. The U.S. entity is restricted to U.S. residents and works alongside parent-coordinated regional entities in Canada and the EU under Eisai Co., Ltd.'s global strategic direction.
Eisai U.S. Neurology firmographics
Firmographics- Name
- Eisai U.S. Neurology
- Legal name
- Eisai Inc.
- Website
- https://eisaineuro.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Eisai U.S. Neurology is the U.S. subsidiary of Japan's Eisai Co., Ltd., developing and commercializing neurology therapeutics primarily for early Alzheimer's Disease through its FDA-approved LEQEMBI franchise, serving patients via healthcare providers, pharmacies, and Magnolia patient support programs.
- Ownership category
- akta.pro rank
Eisai U.S. Neurology industry classification
Industry- Product category
- Neurology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)
Keywords
Where Eisai U.S. Neurology is headquartered
LocationHeadquarters
- HQ city
- Nutley
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Eisai U.S. Neurology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
Distribution channels3 records
Marketing channels4 records
Eisai U.S. Neurology product offering
Product offeringCore offering
Eisai U.S. Neurology develops, manufactures, and markets FDA-approved pharmaceutical therapeutics for neurodegenerative conditions, with a primary focus on Alzheimer's disease. Its flagship product LEQEMBI (lecanemab-irmb) is an amyloid-targeting monoclonal antibody available in IV formulation and a newly approved subcutaneous injection (LEQEMBI IQLIK) for initiation dosing in early Alzheimer's disease. The company also pursues research across tau, neurodegeneration, immunodementia, and sleep-wake disorders (insomnia and narcolepsy).
Product overview
Eisai U.S. Neurology operates as a pharmaceutical company focused on neurodegenerative disease treatments, with LEQEMBI® (lecanemab-irmb) as its flagship FDA-approved product for early Alzheimer's disease. The portfolio includes the original IV formulation and the newly approved LEQEMBI IQLIK® subcutaneous injection for treatment initiation. The company also operates G2D2, a dedicated R&D facility in Cambridge, MA pursuing next-generation immunodementia therapeutics. Research areas include amyloid targeting, tau, neurodegeneration, sleep-wake disorders (insomnia and narcolepsy), and the broader dementia pipeline.
Differentiator
Problem solved
Functional benefit
Brands
- LEQEMBI (lecanemab-irmb): FDA-approved treatment for early Alzheimer's disease, available as IV formulation and subcutaneous injection (IQLIK).
Products and services
- LEQEMBI (lecanemab-irmb) Humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that selectively binds to amyloid-beta (Aβ) protofibrils. FDA-approved for the treatment of early Alzheimer's Disease and administered intravenously. Indicated for healthcare providers and patients with early-stage Alzheimer's Disease.
- LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Subcutaneous injection formulation of lecanemab approved as an initiation dose for early Alzheimer's Disease, offering an alternative to IV administration through an autoinjector delivery system. Improves patient accessibility compared to intravenous infusion.
Quantifiable outcome
- Over 75% of early Alzheimer's patients remained stable and nearly 7% improved over average 17 months of LEQEMBI treatment
Companies that use Eisai U.S. Neurology
Customer profileSegments2 records
Ideal customer profiles2 records
Eisai U.S. Neurology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Eisai U.S. Neurology partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Eisai U.S. Neurology competitors and assessment
Company assessmentDirect peers
- Biogen: Biogen is the co-developer of LEQEMBI and markets competing/successor AD therapies (Aduhelm legacy, pipeline assets) — directly overlapping in disease-modifying Alzheimer's neurology with shared commercial infrastructure.
- Eli Lilly: Eli Lilly markets Kisunla (donanemab), a competing anti-amyloid antibody approved for early Alzheimer's Disease — directly competing with LEQEMBI in the same indication, prescriber base, and payer landscape.
Broad incumbents
- Bristol Myers Squibb: BMS operates a broad neuroscience and specialty therapeutics franchise with growing CNS investment — a larger incumbent competing for neurology talent, payer attention, and acquisition targets in the AD space.
- Roche: Roche developed gantenerumab for Alzheimer's and operates a broad neuroscience portfolio — overlapping with Eisai in CNS drug development but across a wider therapeutic footprint including oncology and rare disease.
- AbbVie: AbbVie maintains a broad neuroscience and specialty CNS portfolio and has invested in neurodegeneration research — a larger incumbent competing for HCP mindshare and pipeline assets in CNS therapeutics.
Regional players
- Otsuka Pharmaceutical: Otsuka is a Japanese-headquartered pharmaceutical peer with overlapping neurology/CNS focus (e.g., Abilify, CNS pipeline) — comparable therapeutic categories but operating primarily through different geographic channels and partner arrangements.
Emerging players
- Cognition Therapeutics: Cognition Therapeutics is developing CT1812 for early Alzheimer's Disease, targeting the sigma-2 receptor — emerging neurology player with overlapping disease-modifying AD ambition but differentiated mechanism.
- Prothena Corporation: Prothena is a clinical-stage biotech developing anti-amyloid and tau-targeted therapies for neurodegenerative diseases — directly comparable pipeline focus on AD/immunodementia mechanisms with Eisai's G2D2 and LEQEMBI franchise.
- Sage Therapeutics: Sage Therapeutics develops CNS therapies including Zurzuvae (postpartum depression) and pipeline neurology assets — comparable CNS-focused biopharma targeting specialty neurology prescribers with overlapping patient access infrastructure.
- Acumen Pharmaceuticals: Acumen Pharmaceuticals is developing sabirnetug, an anti-amyloid antibody for early Alzheimer's Disease — emerging competitor pursuing the same patient population and mechanism class as LEQEMBI.
Market position
Strengths4 records
Weaknesses1 record
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Eisai U.S. Neurology social profiles
Digital presenceEisai U.S. Neurology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eisai U.S. Neurology leadership team
Management profileNumber of profiles
Eisai U.S. Neurology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eisai U.S. Neurology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eisai U.S. Neurology
What does Eisai U.S. Neurology do?
Eisai U.S. Neurology develops, manufactures, and markets FDA-approved pharmaceutical therapeutics for neurodegenerative conditions, with a primary focus on Alzheimer's disease. Its flagship product LEQEMBI (lecanemab-irmb) is an amyloid-targeting monoclonal antibody available in IV formulation and a newly approved subcutaneous injection (LEQEMBI IQLIK) for initiation dosing in early Alzheimer's disease. The company also pursues research across tau, neurodegeneration, immunodementia, and sleep-wake disorders (insomnia and narcolepsy).
When was Eisai U.S. Neurology founded?
Eisai U.S. Neurology was founded in -1. It employs 51 to 100 people.
Where is Eisai U.S. Neurology based?
Eisai U.S. Neurology is headquartered in Nutley, United States, in the North America region.
Who are Eisai U.S. Neurology's main competitors?
Direct peers on record are Biogen and Eli Lilly. Broad incumbents are Bristol Myers Squibb, Roche and AbbVie. Otsuka Pharmaceutical is listed as a regional player. Emerging players are Cognition Therapeutics, Prothena Corporation, Sage Therapeutics and Acumen Pharmaceuticals.
Does Eisai U.S. Neurology have an API?
No public API is recorded for Eisai U.S. Neurology.
What industry is Eisai U.S. Neurology in?
Eisai U.S. Neurology's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.